Health care workers, nursing home residents and other older adults will be first in line.

The search for a treatment for Covid-19 is testing our country’s ability to quickly develop, test, and deploy medications, and several aspects of the U.S. response highlight how the processes for e...

The recent announcement of a corporate divorce between two major Boston medical institutions came as a shock to clinicians and the patients whose care it will inevitably disrupt.

This cross-sectional study assesses Medicare spending on 50 top-selling drugs with limited added clinical benefits using ratings from health technology assessment organizations in Canada, France, and...

This cross-sectional study uses a policy simulation analysis to assess how much Medicare price negotiation would have reduced prescription drug spending if the Inflation Reduction Act of 2022 had...

The CEO of Mass General Brigham topped the scale, earning $5.38 million in 2021.

This cohort study examines the association between price changes for brand-name drugs and out-of-pocket spending by patients with different insurance plans.

This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.

This Viewpoint describes the provisions and limitations of prescription drug pricing reforms enacted by US Congress as part of the Inflation Reduction Act in August 2022.

This cross-sectional study uses a policy simulation analysis to assess how much Medicare price negotiation would have reduced prescription drug spending if the Inflation Reduction Act of 2022 had...

This article examines the budgetary implications of high-priced accelerated approval drugs by estimating Medicare spending on these drugs from 2015 through 2019.

The REVAMP Act, proposed in 2018, would have offered transferrable market exclusivity extension vouchers to reward manufacturers for developing novel antib

This survey-based pilot study explores the frequency and implications of role misidentification experienced by residents at a large academic medical center and evaluates the use of a simple, low-cost...

This study delineates drug coverage, price, and reimbursement regulations in 6 countries, emphasizing the relevance for US policy making.

Congress may have a limited window to pass legislation that could curb skyrocketing drug prices.

Despite claims that the requirement to negotiate prices with Medicare will lead drug companies to delay launches of new medications, that strategy will rarely be financially sensible.

This cross-sectional study assesses Medicaid spending associated with citrate-free vs original adalimumab.

A union could limit our ability for flexibility and put at risk the real-time team experience our doctors in training need to be successful.

Medicare soon will start something it hasn't done in its 58-year history: Negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

Policymakers are considering legislation that would address several well-known problems with the PBM industry. But the bills might not substantially reduce prescription drug spending in the United ...

The Biden administration is pitching three new experiments aimed at bringing down drug prices for Medicare and Medicaid patients.

The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected...

This study uses annual Medicare Part B spending data to examine the potential savings from the drug pricing reforms in the Inflation Reduction Act of 2022.

David Mitchell has filled an important void as a politically savvy patient advocate who was well-funded but didn’t take a penny from the pharmaceutical industry.